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Propaganda or the cost of innovation? Challenging
the high price of new drugs
Concern is growing about the implications of rising drug prices for individuals and health systems
around the world. With little transparency around the costs of drug development, Narcyz Ghinea
and colleagues call for greater accountability from drug companies to ensure a fair price for new
medicines
Narcyz Ghinea doctoral researcher, Wendy Lipworth senior research fellow, Ian Kerridge professor
Centre for Values, Ethics and the Law in Medicine, University of Sydney, Sydney, New South Wales, Australia
In 2014, the IMS Institute for Healthcare Informatics estimated
that, by 2018, global spending on medicines would increase to
almost $1.3tr (£900bn; €1.2tr), an increase of over 30% over
five years.1 Forty per cent of this growth is expected to come
from specialty drugs such as cancer drugs and
immunosuppressants, with predictions that by 2018, such drugs
will account for 50% of drug spending in the United States.2
These estimates may be conservative. For example, the IMS
prediction that global spending on cancer medicines would reach
$100bn by 2018 had already been passed in 2014, with almost
half of this spending associated with targeted, or personalised,
therapies.3 Likewise, the prediction that $100bn will be spent
globally on hepatitis C drugs in the five years up to 2018 seems
conservative given that the estimated cost of treating all patients
with hepatitis C with sofosbuvir (currently priced at about $84
000 for a 12 week course) in the United States alone would be
almost as much as the cost of all other medicines combined.4
The challenge of high drug costs also extends to rare diseases
which, when combined, affect up to 10% (30 million) of
Americans, 40 million Europeans, and 350 million people
worldwide.5 6 Cohen and Felix identified 11 drugs for rare
diseases that have been approved by the US Food and Drugs
Administration (FDA) and that cost more than $225 000 per
patient a year.7 Some of these drugs are not only expensive but
also have high costs per quality adjusted life year (QALY)
gained and may therefore not be considered cost effective
according to the usual thresholds. For instance, enzyme
replacement therapy for Fabry disease was assessed in the
Netherlands to cost €3.3m (£2.6m; $3.6m) per QALY gained,
while alglucosidase alfa for Pompe disease and ivacaftor for
cystic fibrosis have been estimated to cost up to €15m and £1.3m
(€1.7m) respectively per QALY gained.8 9 Such expensive
medicines make the problem of affordability obvious. In
Lithuania, for example, treating 10 patients with
mucopolysaccharidosis VI would cost the equivalent of 17%
of the total national inpatient budget for medicines and medical
aids, and 3% of total reimbursed ambulatory care drug
expenditure.10
Concern is increasing that the rising price of drugs is set to
overwhelm health systems around the world. So what does it
really cost to bring a new medicine to the market, and do these
costs justify the high price?
How much does it cost to develop a new
medicine?
Companies often justify high drug prices on the grounds that
they need to be rewarded for innovation and compensated if
markets are small (as is the case for rare diseases and rare
subsets of common diseases such as cancer). The starting point
for price negotiations therefore should be agreement among all
parties about how much it costs to develop a new medicine.
There is, however, little agreement even on this point.
In 2014, the Tufts University Center for the Study of Drug
Development estimated that the cost of bringing a new drug to
market was $2.6bn,11 over double its 2003 estimate of $1.22bn.12
The researchers used data on the cost and time of drug
development to derive the probability of a drug progressing
from one phase of development to the next; the time a drug
would spend in each phase; and the costs associated with each
phase. The dataset used to derive estimated costs included 106
drugs from 10 drug companies (five of which were among the
largest 10 drug firms) and the dataset used to establish the phase
transition probabilities included 1442 drugs investigated by the
top 50 drug firms.13 To reach their final estimate, the Tufts
researchers loaded the cost of approved drugs with the amount
spent on failed drugs and assumed that 31% of all drug costs
are spent before human trials begin.13 This led them to a figure
of $1.4bn for research and development, with the remaining
$1.2bn arising from the return on capital necessary to attract
investment in pharmaceuticals. The Tufts analysis also showed
that about one in eight drugs make it from first in-human trials
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to market, and that it takes about 30 years for a drug to reach
market, a substantial portion of which is in preclinical research.
The Tufts estimate has, however, been extensively criticised
for ignoring charitable and public spending contributions to
drug development.14 15 Kantarjian and Rajkumar estimate that
85% of basic research into cancer drugs is taxpayer funded.16
And others, such as Harvard pharmacoepidemiologist Jerry
Avorn, have suggested that the Tufts researchers overstated the
returns that investors require and ignored the massive untaxed
cash reserves that drug companies could use to invest in
research.15 A further problem with the Tufts estimate is lack of
transparency about the drugs selected for the analysis. We do
not know, for example, how many were submitted through
accelerated approval programmes, how many were new
biological compounds, how many were treatments for rare
diseases, and to what extent research and development was
supported by public funding.
Tufts’ estimate (which is actually conservative compared with
some others17) is therefore unlikely to allay concerns that drug
companies’ profits vastly outweigh the risks they take. The
industry as a whole makes profits 3-37 times higher than other
industries, with the largest companies making profits of 30%,
yet it invests less in research and development than similar
research dependent industries.18 19 Furthermore, roughly twice
as much is spent on marketing than on innovation, and
companies misleadingly include marketing costs in their
assessments of expenditure on research and development.19 20
Alternative explanations for high costs of
drugs
While drug companies focus on the cost of development to
justify high drug prices, there are several other explanations.
Many of these arise from the fact that the pharmaceutical market
is not actually a “free market” based on supply and demand
with minimal government intervention through taxes, subsidies,
or regulation.21 Rather, the market is highly manipulated, with
numerous government programmes that create special pathways
for product funding and may not be focused on achieving the
best prices—or even fair prices—for drugs.
In addition, the United State has pursued active deregulation
through laws that have limited public payers’ ability to take
advantage of price control strategies.22 This is important globally
because the high prices charged in the United States can have
a knock-on effect on the prices accepted by other countries.23
Generous intellectual property provisions also allow companies
to set and maintain high prices for extended periods.24
Drug prices are driven up further through the industry “gaming”
the system in various ways. For example, companies are able
to maintain high prices through practices such as drug switching
(discontinuing a cheaper drug to force uptake of more expensive
alternatives),25 and “pay to delay” tactics, which reward
competitors for delaying the launch of competing products.26
Drug companies may also launch similar brand name drugs to
extend patent terms,27 aggressively fight generic competitors,
and misuse legislation aimed at stimulating research into rare
diseases to develop blockbuster (non-orphan) drugs and to
extend their patents on existing products.28
There is also no doubt that some companies increase prices
simply because they can. The recent attempt by Turing
Pharmaceuticals to institute a 5000% price hike of
pyrimethamine is a clear illustration of this point.29 Other
examples include the more than 2000% increase in the price of
the tuberculosis drug cycloserine after it was purchased by
Rodelis Therapeutics; the 500% increase in price for the heart
medication nitroprusside after it was purchased by Valeant
Pharmaceuticals; and the more than 1200% increase in the price
of naproxen and esomeprazole for management of pain since
their purchase by Horizon Pharma.29 In the United States the
price of cancer drug imatinib has increased more than threefold
over a decade, even though the market has greatly increased.30
Until recently the burden of expensive medicines on health
systems has gone largely unnoticed. This may be because the
market is ignorant of what drugs really cost or that it consists
of often desperate patients and their carers who are driven by
hope and are relatively insensitive to cost.31 Drug prices may
also be inflated by skewed incentive systems for funding doctors
and hospitals.25
Varied approach to funding medicines
In some countries, the cost of medicines is covered by public
or private insurance schemes. In addition to centralised systems,
special funds may be established, such as the Cancer Drugs
Fund and Hepatitis C Fund in the UK, and the Herceptin
Program and Life Savings Drugs Program in Australia.32-35 Some
patients may also access medicines through expanded access
or compassionate access programmes in which the drug industry
provides drugs freely, or at a discount, to those who can’t afford
them.33 Such schemes can increase access to high cost medicines,
but they can also introduce inequities between and within
countries because not all patients have equal access to these
programmes.12-37 Special government funding schemes can also
create enormous opportunity costs and may represent a form of
price deregulation, where companies who have their products
rejected as not cost effective can seek reimbursement through
less stringent alternative mechanisms. For instance, the breast
cancer drug eribulin was rejected by the UK National Institute
for Health and Care Excellence at the lowest price offered in
Europe, but it was subsequently covered through the UKCancer
Drugs Fund at a price that was among the highest in Europe.37
Concerns about idiosyncratic and inconsistent approaches to
funding medicines have drawn attention to the importance of
robust health technology assessment (HTA) processes, which
are used to determine the cost effectiveness of new drugs, as
well as to drug pricing and the implications this has for fair
access to medicines.
Can we find a “just” price for drugs?
Although a thriving drug industry may be an economic and
financial benefit to governments, the triumphs of pharmaceutical
innovation are hollow victories if they cripple health systems
and generate massive inequities. This raises the question: what
is a “just” price to pay for new medicines?
The question is not easy to answer because a ‘just’ price for a
medicine would have to take account of, at a minimum, the
costs of research and development (minus public and charitable
contributions), regulatory unpredictability and attrition rates,
the extent to which the medicine is innovative and meets a
genuine unmet need, the likely market size, the cost of
manufacturing, and affordability. Affordability, in turn, is
contextual, and varies in terms of national gross domestic
product, income per capita, and national healthcare budget. The
just price for a medicine may therefore vary greatly between
diseases and countries, and disagreement is likely even within
a single setting.
When decision criteria for setting prices cannot be predefined,
it is important to ensure procedural justice, whereby all of the
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factors influencing a decision can be scrutinised by all
stakeholders. One such framework is “accountability for
reasonableness,” which emphasises public access to decisions
and transparency about reasons for decisions; the need for these
reasons to be relevant to “fair minded” participants; mechanisms
to challenge or dispute decisions; and regulation of the process.38
In the case of drug pricing, successful implementation of such
a framework would require much greater transparency and
stakeholder inclusion than is currently the case. While full
transparency and inclusiveness might not be realistic currently,
payers and other key stakeholders should at least know for any
given drug:
• How much has been spent on research directly related to
the development of the specific drug
• How much has been spent on abandoned compounds that
directly led to the development of the specific drug, and
• How much it costs to manufacture each unit of product.
For such a process to be workable, the industry will need to
think beyond corporate confidentiality, fear of losing a
competitive advantage, and perhaps, in some instances, fear of
possible public backlash from revealing how much profit is
made for specific drugs. At the same time, payers will need to
respect commercial realities, avoid demanding prices that do
not reflect the true cost of development, and provide fair
commercial rewards (for example, acknowledging that for
personalisedmedicines, smaller markets and difficulty attracting
investment may necessitate higher per unit prices39). Some
jurisdictions in the United States have attempted to pass
transparency laws that wouldmake such information available.40
In the absence of such laws, payers could encourage
transparency by providing greater leeway in price negotiations
to companies that do disclose costs, thereby putting pressure
on competing companies to do the same.
In addition, we propose using an indication specific pricing
mechanism to take account of the fact that medicines approved
for treating multiple diseases are unlikely to offer the same value
across all indications.41 Better mechanisms are also needed of
managing “indication creep” of high cost medicines and for
discounting prices over time, especially once patents expire.
Price negotiations should not be stubbornly anti-industry. But
equally, those negotiating drug prices can’t be held captive to
industry demands for commercial confidentiality, to threats to
abandon small markets if exorbitant prices are not accepted, or
to unqualified appeals to the “free market.”
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Key messages
The cost of drugs, particularly new biological agents, is overwhelming health budgets around the world
Little is known about how much it really costs to develop new medicines and, therefore, what they are really worth
This limits the ability of public and private payers to negotiate affordable prices and show that they are achieving “value for money”
Basic information about drug development costs needs to be available to both payers and the public to ensure greater accountability
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